Venetoclax-Azacitidine, the new standard of care for AML patients unfit for intensive treatment: A guide for clinical practice

BJH - volume 14, issue 2, march 2023

I. Moors MD, D. Deeren , C. Jacquy MD, PhD, A. Jaspers MD, PhD, T. Kerre MD, PhD, V. Havelange MD, PhD, D. Selleslag MD, C. Spilleboudt MD, N. Straetmans MD, PhD, F. Van Obbergh MD, A. De Voeght MD, S. Anguille MD, PhD, A. Schauwvlieghe MD, PhD, N. De Beule MD, PhD, A. De Becker MD, D. Breems MD, PhD


Acute myeloid leukaemia is an aggressive form of bone marrow cancer with poor prognosis, especially in elderly, unfit patients. The VIALE-A study showed an impressive improvement in complete remission rate and overall survival with the addition of venetoclax, a BCL-2 inhibitor, to azacitidine. This combination therapy is now reimbursed in Belgium for newly diagnosed adult AML patients who are considered unfit for intensive chemotherapy based on age and/or comorbidities. In this article, we provide recommendations on the use of this new combination, as well as on prophylaxis and management of specific side effects.

(BELG J HEMATOL 2023;14(2):59–66)

Read more

O6 Analysis of the impact of mismatches at HLA loci DRB3/4/5 on outcomes after allogeneic stem cell transplantation

BJH - 2018, issue Abstract Book BHS, february 2018

F. Van Obbergh MD, N. Vanlangendonck , A. Van Maanen , P. Van Muylder , A. Ferrant , C. Lambert MD, E. Van den Neste MD, PhD, D. Latinne , X. Poiré MD, PhD

Read more

PP4.2 The clinical relevance of imatinib (Im) plasma trough concentration in patients with chronic myelocytic leukemia (CML) in chronic phase. A Belgian retrospective study

BJH - volume 7, issue Abstract Book BHS, january 2016

F. Van Obbergh MD, L. Knoops MD, PhD, Y. Beguin MD, PhD, C. Graux MD, PhD, S. Benghiat MD, PhD, K. Kargar-Samani , D. Bauwens , A. Efira MD, C. Dubois , C. Springael MD, PhD, L. Montfort , T. Connerotte MD, A. Delannoy , P. Wallemacq

Read more

O.2 Analysis of Phenotype and Outcome in Essential Thrombocythemia with CALR and JAK2 mutations

BJH - volume 6, issue Abstract Book BHS, january 2015

C. AL Assaf , F. Van Obbergh MD, J. Billiet MD, E. Lierman PhD, T. Devos MD, PhD, C. Graux MD, PhD, A.S. Hervent , T. Tousseyn MD, PhD, P. De Paepe MD, PhD, P. Papadopoulos , L. Michaux MD, PhD, P. Vandenberghe MD, PhD

Read more

P2.12 An unusual presentation of cryptococcal meningitis in a patient with lymphoplasmacytic dyscrasia

BJH - volume 5, issue Abstract Book BHS, january 2014

F. Van Obbergh MD, A. Ferrant , D. Wilmes , J. Yombi , L. Knoops MD, PhD, M-C. Vekemans MD, PhD, L. Michaux MD, PhD

Read more

Treatment of peripheral T-cell lymphomas: recommendations of the Belgian Hematological Society (BHS)

BJH - volume 4, issue 3, september 2013

F. Van Obbergh MD, A. Van Hoof MD, PhD, G. Verhoef MD, PhD, D. Dierickx MD, PhD, V. De Wilde MD, PhD, F. Offner MD, PhD, D. Bron MD, PhD, A. Sonet MD, M. André MD, PhD, A. Janssens MD, PhD, C. Bonnet MD, PhD, B. Deprijck MD, P. Zachée MD, PhD, A. Kentos MD, PhD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD


The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each panellist’s expert provided interpretation of the evidence, based on literature review and personal experience. The available evidence was systematically discussed prior to formulating recommendations. A systematic approach to obtain consensus of expert opinion was used. After each meeting, the draft guideline was circulated to all experts for comment and approval. The present guidelines focus on general management of peripheral T-cell lymphomas with special emphasis on more specific disease-adapted strategies.

(BELG J HEMATOL 2013;4(3):90–101)

Read more

P.53 Acute liver failure in a patient with sickle/ beta-thalassemia (S/β)

BJH - 2013, issue BHS Abstractbook, january 2013

F. Van Obbergh MD, C. Lambert MD, O. Ciccarelli , C. Dangoisse , C. Sempoux , L. Knoops MD, PhD, A. Ferrant , L. Michaux MD, PhD, M-C. Vekemans MD, PhD

Read more